Results 1 to 10 of about 123,499 (307)

Polyvalent AIDS vaccines. [PDF]

open access: yesCurr HIV Res, 2010
A major hurdle in the development of a global HIV-1 vaccine is viral diversity. For close to three decades, HIV vaccine development has focused on either the induction of T cell immune responses or antibody responses, and only rarely on both components.
Lu S, Grimes Serrano JM, Wang S.
europepmc   +4 more sources

HIV/AIDS Vaccines: 2018. [PDF]

open access: yesClin Pharmacol Ther, 2018
Human immunodeficiency virus (HIV) has infected 76 million people and killed an estimated 35 million. During its 40‐year history, remarkable progress has been made on antiretroviral drugs. Progress toward a vaccine has also been made, although this has yet to deliver a licensed product. In 2007, I wrote a review, HIV AIDS Vaccines: 2007.
Robinson HL.
europepmc   +4 more sources

Analysis of SARS-CoV-2 variants B.1.617: host tropism, proteolytic activation, cell–cell fusion, and neutralization sensitivity

open access: yesEmerging Microbes and Infections, 2022
SARS-CoV-2 has caused the COVID-19 pandemic. B.1.617 variants (including Kappa and Delta) have been transmitted rapidly in India. The transmissibility, pathogenicity, and neutralization characteristics of these variants have received considerable ...
Li Zhang   +21 more
doaj   +1 more source

HIV-1 pseudoviruses constructed in China regulatory laboratory

open access: yesEmerging Microbes and Infections, 2020
To better evaluate HIV-1 vaccines and therapeutics, the National Institutes for Food and Drug Control of China developed a panel of HIV-1 pseudoviruses including 462 viral strains derived from China, covering the majority of contemporaneous subtypes and ...
Jianhui Nie   +3 more
doaj   +1 more source

Establishment and validation of a pseudovirus neutralization assay for SARS-CoV-2

open access: yesEmerging Microbes and Infections, 2020
Pseudoviruses are useful virological tools because of their safety and versatility, especially for emerging and re-emerging viruses. Due to its high pathogenicity and infectivity and the lack of effective vaccines and therapeutics, live SARS-CoV-2 has to
Jianhui Nie   +17 more
doaj   +1 more source

The antigenicity of SARS-CoV-2 Delta variants aggregated 10 high-frequency mutations in RBD has not changed sufficiently to replace the current vaccine strain

open access: yesSignal Transduction and Targeted Therapy, 2022
Emerging SARS-CoV-2 variants are the most serious problem for COVID-19 prophylaxis and treatment. To determine whether the SARS-CoV-2 vaccine strain should be updated following variant emergence like seasonal flu vaccine, the changed degree on ...
Jiajing Wu   +18 more
doaj   +1 more source

Nipah pseudovirus system enables evaluation of vaccines in vitro and in vivo using non-BSL-4 facilities

open access: yesEmerging Microbes and Infections, 2019
Because of its high infectivity in humans and the lack of effective vaccines, Nipah virus is classified as a category C agent and handling has to be performed under biosafety level 4 conditions in non-endemic countries, which has hindered the development
Jianhui Nie   +7 more
doaj   +1 more source

Development of a Triple-Color Pseudovirion-Based Assay to Detect Neutralizing Antibodies against Human Papillomavirus

open access: yesViruses, 2016
Pseudovirion-based neutralization assay is considered the gold standard method for evaluating the immune response to human papillomavirus (HPV) vaccines.
Jianhui Nie   +3 more
doaj   +1 more source

The rise of companies from emerging markets in global health governance: opportunities and challenges [PDF]

open access: yes, 2014
The article analyses the involvement of pharmaceutical companies from emerging markets in global health governance. It finds that they play a central role as low-cost suppliers of medicines and vaccines and, increasingly, new technologies.
ANNE ROEMER-MAHLER   +23 more
core   +1 more source

Retrospective immunogenicity analysis of seasonal flu H3N2 vaccines recommended in the past ten years using immunized animal seraResearch in context

open access: yesEBioMedicine, 2022
Summary: Background: Influenza A (H3N2) virus (A/H3N2) has complex antigenic evolution, resulting in frequent vaccine strain updates. We aimed to evaluate the protective effect of the vaccine strains on the circulating strains from past ten years and ...
Mengyi Zhang   +11 more
doaj   +1 more source

Home - About - Disclaimer - Privacy